Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain -: art. no. RC209

被引:93
作者
Dörr, J
Bechmann, I
Waiczies, S
Aktas, O
Walczak, H
Krammer, PH
Nitsch, R
Zipp, F
机构
[1] Charite Neurosci Res Ctr, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany
[2] Charite Neurosci Res Ctr, Dept Neurol, Div Neuroimmunol, D-10098 Berlin, Germany
[3] German Canc Res Ctr, Div Apoptosis Regulat, D-69009 Heidelberg, Germany
[4] German Canc Res Ctr, Div Immunogenet Tumour Immunol, D-69009 Heidelberg, Germany
关键词
TRAIL; TRAIL receptor; apoptosis; immune privilege; brain; MS;
D O I
10.1523/JNEUROSCI.22-04-j0001.2002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Apoptosis mediated by members of the tumor necrosis factor (TNF)-nerve growth factor superfamily plays a crucial role in the interaction of the nervous and the immune system. On the one hand, it is involved in the defense mechanisms of the brain, the immune privilege. On the other hand, it is involved in the induction of glial-neuronal cell death in neuroinflammatory diseases. Here, we show that in contrast to the other known death ligands, TNF-related apoptosis-inducing ligand (TRAIL) is not constitutively expressed in the human brain, whereas both apoptosis-mediating and apoptosis-blocking TRAIL receptors are found on neurons, astrocytes, and oligodendrocytes. Thus, the brain differs from other immune-privileged organs, such as the placenta, with the TRAIL receptor-TRAIL system not being part of the immune privilege of the brain. Conversely, this death receptor-ligand system might well play an important role in T cell-mediated autoimmune diseases of the CNS such as multiple sclerosis.
引用
收藏
页数:5
相关论文
共 31 条
  • [1] TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study
    Arnason, BGW
    Jacobs, G
    Hanlon, M
    Clay, BH
    Noronha, ABC
    Auty, A
    Davis, B
    Nath, A
    Bouchard, JP
    Belanger, C
    Gosselin, F
    Thibault, M
    Duquette, P
    Bourgoin, P
    DuBois, R
    Girard, M
    Ebers, GC
    Rice, GPA
    Vandervoort, MK
    Francis, GS
    Duncan, L
    Lapierre, Y
    Freedman, MS
    Christie, SN
    Rabinovitch, HE
    Patry, D
    Murphy, WF
    Peters, S
    McGuiness, SD
    Murray, TJ
    Bhan, V
    Maxner, CE
    Van Dorpe, R
    Oger, JJ
    Nelson, J
    Morrison, W
    Bogle, N
    Beall, S
    Vorobeychick, G
    Hiltbrunner, AV
    Bock, J
    Habil
    Lesslauer, W
    Li, DKB
    Paty, DW
    Zhao, GJ
    [J]. NEUROLOGY, 1999, 53 (03) : 457 - 465
  • [2] Impairment of TNF-receptor-1 signaling but not Fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice
    Bachmann, R
    Eugster, HP
    Frei, K
    Fontana, A
    Lassmann, H
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (05) : 1417 - 1422
  • [3] Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO
  • [4] 2-Y
  • [5] Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO
  • [6] 2-S
  • [7] Bellgrau D, 1999, Int Rev Immunol, V18, P547, DOI 10.3109/08830189909088498
  • [8] The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
    Degli-Esposti, MA
    Dougall, WC
    Smolak, PJ
    Waugh, JY
    Smith, CA
    Goodwin, RG
    [J]. IMMUNITY, 1997, 7 (06) : 813 - 820
  • [9] Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
    DegliEsposti, MA
    Smolak, PJ
    Walczak, H
    Waugh, J
    Huang, CP
    DuBose, RF
    Goodwin, RG
    Smith, CA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) : 1165 - 1170
  • [10] DORR J, 2001, IN PRESS J NEUROIMMU